U-Blot® Research Grade Ladiratuzumab
Ucallm.jpg
$9,999.00
Product details
Background：Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer.
• Zinc and cancer: implications for LIV-1 in breast cancer., PMID:22852056
• Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production., PMID:31009334
• Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting but not depolarizing conditions., PMID:18272141
• A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3)., PMID:23919497
• Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7., PMID:18330719
• Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells., PMID:19852955
• Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy., PMID:21862359
Specifications
| Target | SLC39A6 |
| Reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Humanized |
| Isotype | IgG1-kappa |
| Conjugate/Modification | |
| Modification | |
| Recommended Dilution Ratio | |
| Composition | 0.01M PBS, pH 7.4. |
| Purification Process | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Condition | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | |
| Immunogen | Mammalian Cells |
| Gene Name | |
| Protein Name | |
| Alias | SLC39A6, LIV1, Zrt- and Irt-like protein 6, Zinc transporter ZIP6, ZIP-6, Estrogen-regulated protein LIV-1, Solute carrier family 39 member 6, ZIP6 |
| Species | |
| Gene ID-1 | Q13433 |
| Uniprot | |
| Species.1 | |
| Gene ID | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.1 | |
| Uniprot.2 | |
| Organism-4 | |
| Gene ID-4 | |
| SwissProt-4 | |
| Description | Background：Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer.<br>• Zinc and cancer: implications for LIV-1 in breast cancer., PMID:22852056<br />• Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production., PMID:31009334<br />• Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting but not depolarizing conditions., PMID:18272141<br />• A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3)., PMID:23919497<br />• Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7., PMID:18330719<br />• Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells., PMID:19852955<br />• Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy., PMID:21862359<br /> |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function |
Please login to post questions
Related products
